Skip to Main Content

Paper Details

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Circulation
73
2021
Advanced Prostate Cancer, Cardiovascular Disease, Degarelix, GnRH, Leuprolide, Patients, Prostate Cancer, atherosclerotic cardiovascular disease, degarelix, gonadotropin-releasing hormone, leuprolide, men, myocardial infarction, participants, patients, prostate cancer, stroke
Author NameAffiliation
Renato D LopesDuke Clinical Research Institute, Duke University Medical Center
Celestia S HiganoUniversity of Washington and Fred Hutchinson Cancer Research Center
Per Soelberg SørensenFerring Pharmaceuticals A/S
Christopher P EvansUniversity of California davis
Deepak L BhattBrigham and Women's Hospital Heart and Vascular Center, Harvard Medical School
Matthew T RoeDuke Clinical Research Institute, Duke University Medical Center
Matthew T Roe
John H AlexanderDuke Clinical Research Institute, Duke University Medical Center
  • 1 - 8

Datasets

Release 1.2